• M R Aras, M Albayrak, A Yildiz, S Maral, H B A Ozturk, P Tiglioglu, M Tiglioglu, B Saglam, and F Yilmaz.
• Department of Hematology, University of Health Sciences Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey.
• Niger J Clin Pract. 2022 Aug 1; 25 (8): 1332-1337.

Background And AimThe aim of the study was to examine the demographic, clinical features, treatment responses, and outcomes of Hodgkin lymphoma (HL) patients and to investigate the factors affecting their survival.Patients And MethodsA retrospective analysis was made of patients diagnosed with HL in our department between 2009 and 2019. Treatment regimen, treatment response, and follow-up times were recorded for all patients. Using these data, complete response (CR) rates, overall survival (OS), and progression-free survival (PFS) were calculated. The effects of parameters on survival were investigated with Cox regression analysis.ResultsEvaluation was made of 60 patients with a median age of 33.5 years [18.0-80.0] and mean follow-up duration of 29.34 ± 23.64 months. Median OS and PFS could not be reached with a mean OS of 85.6 months, and PFS of 71.7 months at the final visit. Only initial leukocyte and neurophil count were determined to have a statistically significant impact on survival (OR = 1.004; P = 0.031 vs OR = 0.996; P = 0.036).ConclusionIn HL patients, in addition to the many prognostic scoring systems, leukocyte and neutrophil count can be used as an independent prognostic parameter. Patients with higher leukocyte and lower neutrophil counts at the time of diagnosis should be managed more carefully.

14 keywords...

hide…